EGFR and HER2 exert distinct roles on colon cancer cell functional properties and expression of matrix macromolecules

Biochimica et Biophysica Acta - General Subjects

Volumn 1840, Issue 8, 2014, Pages 2651-2661

  Ellina, Maria Ioanna ^a   Bouris, Panagiotis ^a   Aletras, Alexios J ^a   Theocharis, Achilleas D ^a   Kletsas, Dimitris ^b   Karamanos, Nikos K ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b Laboratory of Cell Proliferation and Ageing Institute of Biology National Center of Science Research Demokritos   (Greece)

Author keywords

Colon cancer; EGFR; Extracellular matrix; HER2; Metalloproteinase; Migration

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CP 724714; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLYPICAN 1; JANUS KINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN; SYNDECAN 4; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; GENE EXPRESSION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UPREGULATION;

COLON CANCER; EGFR; EXTRACELLULAR MATRIX; HER2; METALLOPROTEINASE; MIGRATION;

CACO-2 CELLS; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84903486569     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2014.04.019     Document Type: Article

References (57)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J. Clin. 277 2010 (Co)
2. C. Massie, and I.G. Mills The developing role of receptors and adaptors Nat. Rev. Cancer 6 2006 403 409
3. M. Sibilia, and E.F. Wanger Strain-dependent epithelial defects in mice lacking the EGF receptor Science 269 5221 1995 234 238
4. D.W. Threadgill, A.A. Dlugosz, L.A. Hansen, T. Tennenbaum, U. Lichti, D. Yee, C. LaMantia, T. Mourton, K. Herrup, and R.C. Harris et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype Science 269 5221 1995 230 234
5. J.D. Moyer, E.G. Barbacci, K.K. Iwata, L. Arnold, B. Boman, A. Cunningham, C. DiOrio, J. Doty, M.J. Morin, M.P. Moyer, M. Neveu, V.A. Pollack, L.R. Pustilnik, M.M. Reynolds, D. Sloan, A. Theleman, and P. Miller Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res. 57 1997 4838 4848
6. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogenic-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
7. O.K. Park, T.S. Schaefer, and D. Nathans In vitro activation of Stat3 by epidermal growth factor receptor kinase Proc. Natl. Acad. Sci. U. S. A. 93 1996 (13704-12708)
8. A. Kauffmann-Zeh, G.M. Thomas, A. Ball, S. Prosser, E. Cunningham, S. Cockcroft, and J.J. Hsuan Requirement for phosphtidylinositol transfer protein in epidermal growth factor signaling Science 268 1995 1188 1190
9. R. Sordella, D.W. Bell, D.A. Haber, and J. Settleman Gefitinib- sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways Science 305 2004 1163 1167
10. T. Wada, X.L. Qian, and M.I. Greene Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function Cell 61 7 1990 1339 1347
11. D. Karunagaran, E. Tzahar, R.R. Beerli, X. Chen, D. Graus-Porta, B.J. Ratzkin, R. Seger, N.E. Hynes, and Y. Yarden ErbB-2 is a common auxiliary subunit of NDF- and EGF receptors: implication for breast cancer EMBO J. 15 1996 254 264
12. N.E. Hynes, and G. MacDonald ErbB receptors and signaling pathways in cancer Curr. Opin. Cell Biol. 2009 177 184
13. J.A. McKay, L.J. Murray, S. Curran, V.G. Ross, C. Clarck, G.I. Murray, J. Cassidy, and H.L. McLeod Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases Eur. J. Cancer 38 2002 2258 2264
14. N.E. Hynes, and T. Schlange Targeting ADAMS and ERBBs in lung cancer Cancer Cell 10 2006 7 11
15. J.P. Spano, R. Fagard, J.C. Soria, O. Rixe, D. Khayat, and G. Milano Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives Ann. Oncol. 16 2005 189 194
16. J.S. Ross, and B.J. McKenna The HER-2/neu oncogene in tumors of gastrointestinal tract Cancer Invest. 19 2001 554 568
17. J.R. Grandis, S.D. Drenning, A. Chakraborty, M.Y. Zhou, Q. Zeng, A.S. Pitt, and D.J. Tweardy Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro J. Clin. Invest. 10297 1998 1385 1392
18. J. Albanell, J. Codony-Servat, F. Rojo, J.M. Del Campo, S. Sauleda, J. Anido, G. Raspall, J. Giralt, J. Roselló, R.I. Nicholson, J. Mendelsohn, and J. Baselga Activated extracellular signal- regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatment Cancer Res. 61 17 2001 6500 6510
19. D. Jiang, J. Liang, L.E. Humphrey, H. Yang, and M.G. Brattain Expression of TGFalpha autocrine activity in human colon carcinoma CBS cells is autoregulated and independent of exogenous epidermal growth factor J. Cell. Physiol. 175 2 1998 174 183
20. P.D. Taylor, and A. Howell The therapeutic potential of novel aromatase inhibitors in breast cancer Expert Opin. Investig. Drugs 8 3 1998 269 279
21. A.E. Wakeling Inhibitors of growth factor signaling Endocr. Relat. Cancer 12 2005 S183 S187
22. H.E. Jones, J.M. Gee, K.M. Taylor, D. Barrow, H.D. Williams, M. Rubini, and R.I. Nicholson Development of strategies for the use of anti-growth factor treatments Endoc Relat Cacner 12 2005 S173 S182
23. A. Arora, and E.M. Scholar Role of tyrosine kinase inhibitors in cancer therapy J. Pharmacol. Exp. Ther. 315 2005 971 979
24. E.I. Deryugina, and J.P. Quigley Matrix metalloproteinases and tumor metastasis Cancer Metastasis Rev. 25 2006 9 34
25. W. Huang, R. Chiquet-Ehrismann, J.V. Moyano, A. Garcia-Pardo, and G. Orend Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation Cancer Res. 61 2001 8586 8594
26. R.J. Giordano Heparinase-2 and syndecan-1 in colon cancer: the ugly docking or the beautiful swans? Eur. J. Gastroenterol. Hepatol. 2008 716 718
27. X.N. Stahtea, A.E. Roussidis, I. Kanakis, G.N. Tzanakakis, G. Chalkiadakis, D. Mavroudis, D. Kletsas, and N.K. Karamanos Imatinib inhibits colorectal cancer growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP-2 activation Int. J. Cancer 121 12 2007 2808 2814
28. K. Hotary, E. Allen, A. Punturieri, I. Yana, and S.J. Weiss Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type metalloproteinases 1,2 and 3 J. Cell Biol. 149 2000 1309 1323
29. H. Nagase, R. Visse, and G. Murphy Structure and function of matrix metalloproteinases and TIMPs Cardiovasc. Res. 69 2006 562 573
30. M. Toth, and M. Bernardo Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)- MMP-dependent activation of pro-MMP-2 J. Biol. Chem. 275 2000 41415 41423
31. R.E. Hewitt, K.E. Brown, M. Corcoran, and W.G. Stetler-Stevenson Increased expression of tissue inhibitor of metalloproteinase type 1 (TIMP-1) in a more tumorigenic colon cancer cell line J. Pathol. 192 2000 455 459
32. E.M. Spiers, G.S. Lazarus, and B. Lyons-Giordano Expression of plasminogen activators in basal cell carcinoma J. Pathol. 178 1996 240 246
33. H. Morgan, and P.A. Hill Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity Cancer Cell Int. 5 2005 1
34. Ch. Gialeli, A.D. Theocharis, D. Kletsas, G.N. Tzanakakis, and N.K. Karamanos Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab Invest. New Drugs 2012 10.1007/s10637-012-9875
35. A.D. Siddiqui, and B. Piperdi KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy Ann. Surg. Oncol. 17 4 2010 1168 1176
36. L.A. Fields, D.A. Rinaldi, C.A. Henderson, C.J. Germond, L. Chu, K.J. Brill, L.H. Leopold, and M.S. Berger An open-label multicenter phase II study of oral Lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer J. Clin. Oncol. 23 2005 3583
37. H. Yamaquchi, J. Wyckoff, and J. Condeelis Cell migration in tumors 17 5 2005 559 564
38. P. Fried, and K. Wolf Tumour-cell invasion and migration: diversity and escape mechanisms Nat. Rev. 2003 10.1038/nrc/078
39. E. Giannopoulou, A. Antonacopoulou, K. Floratou, Papavassiliou, and H.P. Kalofonos Dual targeting of EGFR and HER-2 in colon cancer cell lines Cancer Chemother. Pharmacol. 63 2009 973 981
40. Y. Zhou, S. Li, Y.P. Hu, J. Wang, J. Hauser, A.N. Conway, M.A. Vinci, L. Humphrey, E. Zborowska, J.K. Wilson, and M.G. Brattain Blockage of EGFR and ErbB-2 by the novel dual EGFR and ErbB-2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis Cancer Res. 66 2006 404 411
41. Ch. Gialeli, D. Kletsas, D. Mavroudis, H.P. Kalofonos, G.N. Tzanakakis, and N.K. Karamanos Targeting epidermal growth factor receptor in solid tumor: critical evaluation of the biological importance of the therapeutic monoclonal antibodies Curr. Med. Chem. 16 29 2009 3797 3804
42. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, and A. Ullrich et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
43. E. Ito, I. Yana, C. Fujita, A. Irifune, M. Takeda, A. Madachi, S. Mori, Y. Hamada, N. Kawaquchi, and N. Matsuura The role of MT2-MMP in cancer progression Biochem. Biophys. Res. Commun. 393 2010 222 227
44. Z.S. Zenq, A.M. Cohen, Z.F. Zhang, W. Stetler-Stevenson, and J.G. Guillem Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastasis Clin. Cancer Res. 1 1995 889 906
45. L. Nakopoulou, I. Giannopoulou, K. Stefanaki, E. Panayotopoulou, I. Tsirmpa, P. Alexandrou, J. Mavrommatis, S. Katsarou, and P. Davaris Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis J. Pathol. 197 2002 307 313
46. K. Dano, N. Behrendt, G. Hoyer-Hansen, M. Johnsen, L.R. Lund, M. Plouq, and J. Romer Plasminogen activation and cancer Thromb. Haemost. 93 2005 676 681
47. R.L. Shapiro, J.G. Duquette, D.F. Roses, I. Nunes, M.N. Harris, H. Karmino, E.L. Wilson, and D.B. Rifkin Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals Cancer Res. 56 1996 3597 3604
48. T.I. Frandsen, C. Holst-Hansen, B.S. Nielsen, U. Christensen, J.R. Nyenqaard, P. Carmeliet, and N. Brunner Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model Cancer Res. 61 2001 532 537
49. J. Grondah-Hansen, E. Ralfkiaer, L.T. Kirkeby, P. Kristensen, L.R. Lund, and K. Dano Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans Am. J. Pathol. 138 1991 111 117
50. V. Constontini, A. Sidoni, R. Deveglia, O.A. Cazzato, G. Belleza, I. Ferri, and G.G. Nenci Combined overexpression of urokinase, urokinase receptor, and plasminogen activator-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign and malignant breast tissues Cancer 77 1996 1079 1088
51. S.R. Harvey, S.N. Sait, Y. Xu, J.L. Bailey, R.M. Penetrante, and G. Markus Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immonohistochemistry and in situ hybridization Am. J. Pathol. 155 1999 1115 1120
52. W. Liu, E.D. Litwack, M.J. Stanley, K.J. Langford, A.D. Lander, and R.D. Sanderson Heparan Sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions J. Biol. Chem. 273 1998 22825 22832
53. J. Kleeff, S. Wildi, A. Kumbasar, H. Friess, A.D. Lander, and M. Korc Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells Pancreas 19 1999 281 288
54. A.D. Theocharis, S.S. Skandalis, G.N. Tzanakakis, and N.K. Karamanos Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting FEBS J. 19 2010 3904 3923
55. R.V. Iozzo, and N.K. Karamanos Proteoglycans in health and disease: emerging concepts and future directions FEBS J. 19 2010 3863
56. S.S. Bacus, C.R. Zelnick, D.M. Chin, Y. Yarden, D.B. Kamisky, J. Bennington, D. Wen, J.N. Marcus, and D.L. Page Medullary carcinoma is associated expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior Am. J. Clin. Pathol. 102 1994 S13 S14 (Suppl.)
57. A. Citri, I. Alroy, S. Lavi, C. Rubin, W. Xu, N. Grammatikakis, C. Patterson, L. Neckers, D.W. Fry, and Y. Yarden Dual-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy EMBO J. 21 2002 2407